 |
| Anno II | Numero 9 | Gennaio 2017 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma |
| Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor … |
| Continua a leggere |
| Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors |
| Abscopal effect is a rare phenomenon characterized by tumor regression of untreated metastatic lesions after a local therapy (eg, radiotherapy). We studied the probability of abscopal effect with radiotherapy associated with anti-programmed death cell 1 (PD1) therapy after progression on anti-PD1. This study is a retrospective analysis of patients treated with nivolumab or pembrolizumab for melanoma, non-small cell lung cancer (NSCLC) and renal cancer at Antônio Ermírio de Moraes Oncology Center … |
| Continua a leggere |
| Tim-3 expression on tumor-infiltrating PD-1+CD8+T cells correlates with poor clinical outcome in renal cell carcinoma |
| Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). A second validation cohort measured the same parameters by cytometry. The percentage of tumor-infiltrating CD8+T cells … |
| Continua a leggere |
| Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action |
| Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several genes. Loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene is a very common finding in RCC and leads to up-regulation of hypoxia-inducible factor (HIF)-responsive genes accountable for angiogenesis and cell growth, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). Binding of these proteins to their cognate tyrosine kinase receptors on endothelial … |
| Continua a leggere |
| Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy |
| Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in clinical development and is typically based on tumor response, which may not fully represent the potential for improved overall survival. Here, we describe an integrated approach which incorporates clinical safety and efficacy data with data obtained from analyses of dose-/exposure-response … |
| Continua a leggere |
| Appuntamenti AIOM |
Aggiornamenti in Oncologia: Iponatriemia |
| Verona, 26 – 27 gennaio 2017 |
| Innovative Therapy, Monoclonal Antibodies and Beyond – 7th Edition |
| Milano, 27 gennaio 2017 |
| Metodologia della Ricerca Clinica Corso teorico pratico: “Come si scrive un protocollo di ricerca clinica” |
| Negrar, 31 gennaio – 1 febbraio 2017 |
| Revisioni Sistematiche e Meta-Analisi |
| Negrar, 10 – 11 febbraio 2017 Iscrizioni entro il 3 febbraio |
| Corso Base di Formazione in Psiconcologia per Psicologi e Medici XX Edizione |
| Milano, 20 – 23 febbraio 2017 (I modulo) Milano, 27 – 30 marzo 2017 (II modulo) |
| AIOM Post ASCO GU Review UPDATES and NEWS from the Genitourinary Cancers Symposium in Orlando, FL, USA |
| Milano, 3 marzo 2017 |
| Studi Clinici: Metodologia A good foundation |
| Negrar (VR), 8 – 9 marzo 2017 |
| Studi Clinici: Criticità Interpretative Confidence, directness, relevance |
| Negrar (VR), 24 – 25 marzo 2017 |
| Immunoterapia nei Tumori del Polmone e dell’Urotelio A che punto siamo? |
| Roma, 27 – 28 marzo 2017 |
| Conferenza Nazionale CIPOMO La gestione del rischio in oncologia tra sicurezza e qualità |
| Ascoli Piceno, 31 marzo – 1 aprile 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |